secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0000950170-24-110177
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar halts lupus trial after 4 deaths; IDMC recommends stop
------------------------------------------------------------

- Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.
- IDMC recommendation after review of 4 Grade 5 (fatal) serious adverse events in Philippines and Argentina.
- Three fatalities showed common symptom pattern and proximity to dosing; additional non-fatal SAEs with similar pattern.
- Kezar remains blinded to treatment arms; no prior deaths or serious opportunistic infections in earlier trials.
- PORTOLA trial in autoimmune hepatitis continues enrollment; no Grade 4 or 5 SAEs observed there to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/0000950170-24-110177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/kzr-20240930.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-110177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer